Crizotinib: from discovery to accelerated development to front-line treatment.
Name:
Crizotinib- from discovery to ...
Size:
202.0Kb
Format:
PDF
Description:
Main article
Affiliation
Christie NHS Foundation Trust, Institute of Cancer Sciences, University of Manchester, ManchesterIssue Date
2016-09
Metadata
Show full item recordAbstract
Non-small-cell lung cancer (NSCLC) is associated with a poor prognosis and low survival rates, providing a strong rationale for the development of new treatment options. The discovery of ALK gene rearrangements in a subset of NSCLC specimens and the identification and development of the first-in-class ALK inhibitor crizotinib provided a personalised treatment option for patients with advanced ALK-positive NSCLC. Crizotinib demonstrated rapid and durable responses in advanced ALK-positive NSCLC patients in phase I and II studies, leading to accelerated FDA approval. Subsequent evaluation in phase III studies showed that crizotinib improved progression-free survival compared with platinum-based doublet chemotherapy in previously untreated patients and compared with pemetrexed or docetaxel in previously treated patients. Crizotinib was shown to have an acceptable safety profile and also to improve quality of life and symptom scores. Overall, crizotinib has been shown to provide a valuable first- and second-line treatment option and is now the first-line standard of care for patients with advanced ALK-positive NSCLC.Citation
Crizotinib: from discovery to accelerated development to front-line treatment. 2016, 27(Suppl 3):iii35-iii41 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdw304PubMed ID
27573754Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw304
Scopus Count
Collections
Related articles
- Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.
- Authors: Frampton JE
- Issue date: 2013 Dec
- FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
- Authors: Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R
- Issue date: 2014 Oct
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
- Authors: Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE 1014 Investigators
- Issue date: 2014 Dec 4
- ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
- Authors: Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C
- Issue date: 2013 Mar